Vilya

Always one of the best meeetings of the year!

Vilya is here in San Diego! We are proud to join the American Association for Cancer Research Annual Meeting 2026 this April 17–22. Our team is heading to #AACR26 to engage with the global research community as we advance our mission to cure the incurable through intelligent drug design. We are proud to be building an independent, leading biotech dedicated to solving the most challenging unmet needs in oncology. Meet Our Representatives This year, Vilya will be represented by: Cyrus Harmon Michelle Marques Howarth, Ph.D. We look forward to discussing how foundational computational approaches allow us to tap into uncharted chemical space, designing novel medicines to precisely target disease biology and fundamentally improve human health. 📅 When: April 17 – April 22 📍 Where: San Diego, CA 🔗 Learn more about our mission: https://vilyatx.com/ 📧 Email: hello@vilyatx.com #AACR26 #CancerResearch #Biotech #DrugDiscovery #Vilya #Oncology #ComputationalBiology #SanDiegoScience #LifeSciences

We are excited to announce that Vilya will be attending the American Association for Cancer Research Annual Meeting 2026 in San Diego from April 17–22. Our team is heading to #AACR26 to engage with the global research community as we work toward our mission: Building an independent, leading biotech company founded on intelligent drug design to cure the incurable. Representing Vilya this year are Cyrus Harmon, and Michelle Marques Howarth, Ph.D. We look forward to discussing how the revolution in technology and biology can be harnessed to better human health and solve the most challenging unmet medical needs in oncology today. If you’re attending, let’s connect and explore the future of precision medicine together. 📅 When: April 17 – April 22 📍 Where: San Diego, CA 🔗 Learn more about our mission: https://vilyatx.com/ 📧 Email: hello@vilyatx.com #AACR26 #CancerResearch #Biotech #DrugDiscovery #Vilya #Oncology #ComputationalBiology #SanDiegoScience #LifeSciences

We’re excited to have our Co-Founder and CTO, Patrick Salveson, Ph.D. speaking today at Drug Discovery Chemistry in San Diego! Patrick will be diving into how Vilya builds state-of-the-art structure prediction models that succeed where third-generation models struggle—specifically in designing and optimizing macrocyclic peptides with non-canonical amino acids. Today at 4:00 PM Pacific If you’re at the conference, don’t miss this look into some of the work going on at Vilya. 🔗 Learn more about Vilya: https://vilyatx.com/

Introducing Vilya-1—an all-atom foundation model designed to accurately model and design macrocycles and peptides with non-canonical chemistry, creating new possibilities for drug discovery. Vilya-1 sets a new state-of-the-art for macrocycle structure prediction and, unlike existing methods, performs equally well on peptides built from non-canonical amino acids, opening the door to a new world of computationally-designed molecules with attractive drug-like properties. At Vilya, we believe modern peptide therapeutics require far more than binding alone. Achieving the right balance of stability, permeability, and specificity often demands chemical diversity beyond what canonical amino acids can offer. Reaching challenging intracellular targets means moving past the limits of existing design tools and into previously unexplored chemical space. 🔗 Learn more and read the technical report: https://lnkd.in/gw99UPkW 🔗 Join us: https://lnkd.in/gGRhYGzP

Our updated website is live! Connecting science, computation, and collaboration. We’re excited to share our new website and refreshed brand identity — capturing how Vilya unites computation, chemistry and experimental biology to design de novo macrocyclic therapeutics with precision. Created in close collaboration with the design studio Eatch Interactive, the platform is built for connection — speaking to scientists, pharma partners, and investors who share our ambition to expand what’s possible in drug discovery. Discover the new Vilya: https://vilyatx.com/

Vilya will be at BIO-EUROPE 2025 in Vienna, Austria from November 3–5. Our CEO & President, Cyrus Harmon, PhD, and our VP of Operations, Daniel W., will be there to connect with potential partners and explore opportunities to advance computational innovation in macrocyclic peptide discovery. If you’re attending, we’d love to meet with you! You can find us through partneringONE®. #BIOEUROPE #DrugDiscovery #Partnerships #Biotech #Vilya

Vilya Featured in Nature Biotechnology’s Editor’s Pick We’re honored that Nature Biotechnology has selected Vilya for its Editor’s Pick, recognizing our work to advance macrocycle drug discovery and design. Our mission is to unlock the potential of ‘Goldilocks’ macrocycles, molecules that can engage challenging protein–protein interfaces, previously requiring large molecules such as antibodies, while remaining small enough for oral delivery. These powerful molecules could address proteins once considered ‘undruggable’, opening the door to new treatments in immunology, oncology, and beyond. The feature highlights our innovative platform developed by co-founder and CTO Patrick Salveson, Ph.D. together with a world-class team of scientists, engineers, and the leadership of Cyrus Harmon. Together, we’re advancing a pipeline that begins with our integrin α4β7 program for inflammatory bowel disease, with more programs on the horizon. We’re proud to be pushing the boundaries of drug design and look forward to sharing more as we move our pipeline forward. 🔗 Read the full feature here: https://lnkd.in/g24zZtAA #Vilya #DrugDiscovery #Macrocycles #Biotechnology #NatureBiotechnology

We’re honored to be featured in GeekWire’s latest roundup of Seattle-area biotech innovators and thrilled that Vilya is among the spotlighted companies! As a two site company rooted in Seattle and innovating in Seattle and South San Francisco, we are grateful to both communities for their world class scientific talent, pioneering research institutions, and collaborative spirit that fuel our mission: creating a novel class of medicines to precisely target disease biology by computationally exploring uncharted chemical space. Thank you to GeekWire for featuring our work, to JPMorganChase for presenting the GeekWire 200, and to our team, partners, and investors for powering our journey to transform drug discovery. https://lnkd.in/gnksz_sP

Vilya is headed to BIO 2025! Join Cyrus Harmon, PhD (CEO & President) and Daniel W. (VP, Operations) in Boston, June 16–19 to explore how we are harnessing the power of our platform to go after previously impossible targets. Find us through the Conference Partnering System or email us at partnering@vilyatx.com #BIO2025 #Vilya #Partnering #DrugDiscovery #Macrocycles